medigraphic.com

2005, Número 2

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2005; 43 (2)


Farmacovigilancia III. La experiencia internacional

Rodríguez BL, García VJL, Giral BC, Hernández SD, Jasso GL

Idioma: Español
Referencias bibliográficas: 38
Paginas: 131-140
Archivo PDF: 99.36 Kb.


RESUMEN

El presente trabajo es el tercero de una serie dedicada a la farmacovigilancia, que en esta ocasión se enfoca a la experiencia internacional de las reacciones adversas. Se destacan los países con mayor número acumulado de reportes, y se muestra cómo ese orden cambia cuando se ajusta el número de reportes por país por millón de habitantes/año. A continuación se muestra en orden decreciente el número de reportes de 20 clases terapéuticas de medicamentos, incorporando en cada una de ellas las explicaciones más plausibles de su mayor frecuencia y, finalmente, se señala el número de reportes acumulados con base en sus manifestaciones clínicas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1. Rodríguez-Betancourt JL, García-Vigil JL, Giral-Barnés C, Hernández-Santillán D, Jasso-Gutiérrez L. Farmacovigilancia I. El inicio. Rev Med IMSS 2004;42(4):327-329.

  2. 2. Rodríguez-Betancourt JL, García-Vigil JL, Giral-Barnés C, Hernández-Santillán D, Jasso-Gutiérrez L. Farmacovigilancia II. Las reacciones adversas de los medicamentos y el Programa Internacional de Moni-toreo de los Medicamentos. Rev Med IMSS 2004;42(5): 419-423.

  3. 3. Lindquist M. Seeing and observing in international pharmacovigilance. Uppsala, Sweden: The Uppsala Monitoring Centre; 2003.

  4. 4. WHO Collaborating Centre for International Drug Monitoring. Viewpoint Part 1. Uppsala, Sweden: The Uppsala Monitoring Centre; 2002.

  5. 5. Secretaría de Salud. Base de datos del Centro Nacional de Farmacovigilancia. México, D. F.

  6. 6. Green AG. Understanding NSAIDS: from aspirin to COX-2. Clin Cornerstone 2001;3(5):50-59.

  7. 7. Rawlins MD, Thomas SHL. Mechanisms of adverse drug reactions. En: Davies D, Ferner RE, Glandville H, editors. Davies’s textbook of adverse drug reactions. London, UK: Chapman and Hall Medical; 1998. p. 40-64.

  8. 8. Klasco RK (Ed): DRUGDEX ® System. Thompson MICROMEDEX, Greenwood Village, Colorado (Vol. 21 9/2004).

  9. 9. Kando JC, Wells BG. Depressive disorders. En: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy. Connecticut, USA: Appleton and Lange; 1999. p. 1141-1160.

  10. Majeroni BA, Hess A. The pharmacologic treatment of depression. J Am Board Fam Pract 1998;11(2):127-139.

  11. Jacobson RM. Vaccine safety. Immunol Allergy Clin N Am 2003;23(4):589-603.

  12. Mandell GL, Petri WA. Fármacos antimicrobianos. En: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman GA, editores. Las bases farmacológicas de la terapéutica. México: McGraw-Hill Interamericana; 1996. p. 1156.

  13. Gleckman RA, Czachor JS. Antibiotic side effects. Semin Respir Crit Care Med 2000;21(1):53-60.

  14. Creed L. Antithrombotic drugs for secondary stroke prophylaxys. Pharmacotherapy 2001;21(4):452-463.

  15. Knowles SR. Adverse effects of antiepileptics. Can J Clin Pharmacol 1999;6(3):137-147.

  16. Anderson GD. Children versus adults: pharmaco-kinetic and adverse–effect differences. Epilepsia 2002;43(Suppl)3:63-69.

  17. Tanaka E. Clinically Significant Pharmacokinetic Drug Interactions between antiepileptic drugs. J Clin Pharm Ther 1999;24(2):87-92.

  18. Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;67(6):855-870.

  19. Kurosawa S. What is important in treating elderly with H2 receptor antagonists. Nippon Rinsho 2002; 60(8):1613-1617.

  20. Fisher AA, Le Couter DG. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf 2001; 24(1):39-57.

  21. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabenprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000;40(1):52-62.

  22. Talbert RL. Hyperlipidemia. En: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy. Connecticut, USA: Appleton and Lange; 1999. p. 350

  23. Steckelings UM, Artuc M, Wellschlager T, Wichstutz S, Henz BM. Angiotensin-converting enzyme inhibitors as inducers of cutaneous reactions. Acta Derm Venereol 2001;81(5):321-325.

  24. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001;41(6):875-886.

  25. Forinash AB, Evans SL. New hormonal contra-ceptives: a comprehensive review of the lite. Pharmaco-therapy 2003;23(12):1573-1591.

  26. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288(3):321-333.

  27. Campbell ML, Mathys ML. Pharmacologic options for the treatment of obesity. Am J Health-Syst Pharm 2001; 58(14):1301-1308.

  28. Hash RB. Intravascular radiographic contrast media: issues for family physicians. J Am Board Fam Pract 1999;12(1):32-42.

  29. Reisine T, Pasternak. Opioid Analgesics and Antagonists. En: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman GA, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. New York, USA: McGraw-Hill; 1996.

  30. Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy 2004;24(6):776-783.

  31. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender related effects on metoprolol pharmacokinetics and pharmacodinamics in healthy volunteers. Clin Pharmacol Ther 1999;66(6):594-601.

  32. Wolf JE. Acne and Rosacea: differential diagnosis and treatment in the primary care setting. Medscape CME 2003.

  33. Vaillant L. Mechanisms of cutaneous drug reactions. Rev Pract 2000;50(12):1294-1299.

  34. Assem ES. Drug Allergy and tests for its detection. En: Davies DM, Ferner RE, Glanville H, editors. Davies’s textbook of adverse drug reactions. London, UK: Chapman and Hall Medical; 1998. p. 790.

  35. Bateman DN, Aziz EE. Gastrointestinal disorders. En: Davies DM, Ferner RE, Glanville H, editors. Davies’s textbook of adverse drug reactions. London, UK: Chapman and Hall Medical; 1998. p. 259.

  36. Blain PG, Lane RJM. Neurological disorders. En: Davies DM, Ferner RE, Glanville H, editors. Davies’s textbook of adverse drug reactions. London, UK: Chapman and Hall Medical; 1998. p. 585.

  37. Ashton CH, Young AH. Drug-induced psychiatric disorders. En: Davies DM, Ferner RE, Glanville H, editors. Davies’s textbook of adverse drug reactions. London, UK: Chapman and Hall Medical; 1998. p. 669-670.

  38. Martin WE. Hazards of medication. Philadelphia, USA: J. B. Lippincott Company; 1971. p. 226.




2020     |     www.medigraphic.com